Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium
Kymera Therapeutics announced three poster presentations at the EORTC-NCI-AACR Symposium, showcasing new preclinical data from its targeted protein degradation (TPD) platform. The presentations focus on KT-253, the company's MDM2 degrader currently in Phase 1 clinical trials for solid tumors and hematological malignancies. Using machine learning, researchers identified tumor types sensitive to KT-253, including acute myeloid leukemia, neuroendocrine tumors, and specific solid tumors. Additional presentations highlight the company's platform capabilities in developing CDK2 degraders and the effectiveness of MDM2 degraders in Merkel cell carcinoma.
Kymera Therapeutics ha annunciato tre presentazioni di poster al Simposio EORTC-NCI-AACR, presentando nuovi dati preclinici dalla sua piattaforma di degradazione proteica mirata (TPD). Le presentazioni si concentrano su KT-253, il degradatore di MDM2 dell'azienda attualmente in fase di sperimentazione clinica di Fase 1 per tumori solidi e malignità ematologiche. Utilizzando l'apprendimento automatico, i ricercatori hanno identificato i tipi di tumore sensibili a KT-253, tra cui leucemia mieloide acuta, tumori neuroendocrini e specifici tumori solidi. Ulteriori presentazioni evidenziano le capacità della piattaforma dell'azienda nello sviluppo di degradatori di CDK2 e l'efficacia dei degradatori di MDM2 nel carcinoma a cellule di Merkel.
Kymera Therapeutics anunció tres presentaciones de carteles en el Simposio EORTC-NCI-AACR, mostrando nuevos datos preclínicos de su plataforma de degradación de proteínas dirigida (TPD). Las presentaciones se enfocan en KT-253, el degradador de MDM2 de la compañía que actualmente está en ensayos clínicos de Fase 1 para tumores sólidos y malignidades hematológicas. Usando aprendizaje automático, los investigadores identificaron tipos de tumores sensibles a KT-253, incluyendo leucemia mieloide aguda, tumores neuroendocrinos y tumores sólidos específicos. Presentaciones adicionales destacan las capacidades de la plataforma de la compañía para desarrollar degradadores de CDK2 y la efectividad de los degradadores de MDM2 en el carcinoma de células de Merkel.
Kymera Therapeutics는 EORTC-NCI-AACR 심포지엄에서 세 가지 포스터 발표를 진행하며, 표적 단백질 분해(TPD) 플랫폼의 새로운 전임상 데이터를 선보였습니다. 발표는 현재 고형 종양 및 혈액 악성종양에 대한 1상 임상 시험 중인 회사의 MDM2 분해제인 KT-253에 초점을 맞추고 있습니다. 머신 러닝을 사용하여 연구자들은 급성 골수성 백혈병, 신경내분비 종양 및 특정 고형 종양을 포함하여 KT-253에 민감한 종양 유형을 파악했습니다. 추가 발표에서는 CDK2 분해제를 개발하는 데 있어 회사의 플랫폼 능력과 메르켈 세포 암종에서 MDM2 분해제의 효과를 강조합니다.
Kymera Therapeutics a annoncé trois présentations d'affiches au Symposium EORTC-NCI-AACR, présentant de nouvelles données précliniques de sa plateforme de dégradation ciblée des protéines (TPD). Les présentations sont centrées sur KT-253, le dégradateur de MDM2 de l'entreprise qui est actuellement en essais cliniques de Phase 1 pour les tumeurs solides et les malignités hématologiques. Grâce à l'apprentissage automatique, les chercheurs ont identifié des types de tumeurs sensibles à KT-253, y compris leucémie myéloïde aiguë, tumeurs neuroendocrines et tumeurs solides spécifiques. Des présentations supplémentaires soulignent les capacités de la plateforme de l'entreprise dans le développement de dégradateurs de CDK2 et l'efficacité des dégradateurs de MDM2 dans le carcinome à cellules de Merkel.
Kymera Therapeutics kündigte drei Posterpräsentationen beim EORTC-NCI-AACR-Symposium an, die neue präklinische Daten von seiner Plattform zur gezielten Proteinvernichtung (TPD) präsentieren. Die Präsentationen konzentrieren sich auf KT-253, den MDM2-Vernichter des Unternehmens, der sich derzeit in klinischen Phase-1-Studien für solide Tumoren und hämatologische Malignome befindet. Mithilfe von maschinellem Lernen identifizierten die Forscher Tumortypen, die empfindlich auf KT-253 reagieren, darunter akute myeloische Leukämie, neuroendokrine Tumoren und spezifische solide Tumoren. Weitere Präsentationen heben die Fähigkeiten der Plattform des Unternehmens zur Entwicklung von CDK2-Vernichtern sowie die Wirksamkeit von MDM2-Vernichtern bei Merkelzellkarzinom hervor.
- KT-253 demonstrated effectiveness against multiple tumor types in preclinical studies
- Machine learning framework successfully identified sensitive tumor populations
- Phase 1 clinical trial for KT-253 is ongoing
- None.
Insights
The presentation of preclinical data for KT-253, an MDM2 degrader, reveals significant progress in biomarker identification and patient population targeting. The machine learning framework's identification of sensitive tumor types, particularly in AML, neuroendocrine tumors and specific solid tumors, demonstrates promising clinical applications.
The research on CDK2 degraders shows enhanced potency compared to traditional inhibitors, particularly in CCNE1-amplified cancers. This dual-targeting mechanism of both CDK2 and Cyclin E represents an innovative approach in cancer treatment. However, these are still early-stage findings, with KT-253 only in Phase 1 trials, meaning significant clinical validation is still needed.
WATERTOWN, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that new preclinical data from its innovative TPD platform will be presented across three poster presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The presentations include new data on its preclinical biomarker-based approach for KT-253, its MDM2 degrader.
“We have built industry leading knowledge and capabilities that we are leveraging to explore the applicability of our platform, including developing new therapeutic hypotheses to assess the potential of protein degradation to address oncogenic proteins in validated signaling pathways,” said Juliet Williams, PhD, Head of Research, Kymera Therapeutics. “As seen in our presentations at the EORTC-NCI-AACR Symposium, we’ve created a toolbox of integrated approaches to accelerate the discovery and development of transformative degrader medicines.”
New data highlights the Company’s research efforts to identify patient populations sensitive to the KT-253 degrader mechanism and define biomarkers associated with an acute apoptotic response in tumors. Using an innovative machine learning framework to develop a predictive signature, the results identified tumor types sensitive to KT-253 that are consistent with preclinical and early clinical findings, including acute myeloid leukemia (AML), neuroendocrine tumors, and subsets of solid tumors with or without neuroendocrine features. KT-253 is in a Phase 1 clinical trial to evaluate its potential as a treatment for solid tumors and hematological malignancies.
The Company will also present a poster highlighting its innovative platform capabilities and the case study of the use of targeted protein degradation to provide improved potency and selectivity over traditional small molecule inhibitors for CDK2, a cell cycle regulator and key protein involved in several cancers.
Presentations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Poster Number: PB283
Title: Predictive Markers of Response to the MDM2 Degrader KT-253
Presenter: Nancy Dumont, PhD, Director, In Vivo Pharmacology
Poster Number: PB032
Title: The MDM2 degraders KTX-049 and KT-253 are highly active in wild-type TP53 (WT p53) Merkel cell carcinoma (MCC)
Presenter: Yogesh Chutake, PhD, Associate Director, Translational Medicine
Poster Number: PB092
Title: CDK2 heterobifunctional degraders co-degrade CDK2 and Cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
Presenter: Nicholas Kwiatkowski, PhD, Associate Director, Biological Sciences
Copies of the EORTC-NCI-AACR poster presentations will be available in conjunction with the conference sessions within the Resource Library section of Kymera's website.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Kymera is also progressing degrader oncology programs that target undrugged or poorly drugged proteins to create new ways to fight cancer. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit www.kymeratx.com or follow us on X or LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about our expectations regarding its Targeted Protein Degradation platform and the clinical development and outcomes of KT-253. The words "may," "might," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "expect," "estimate," "seek," "predict," "future," "project," "potential," "continue," "target" and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from any forward-looking statements contained in this press release, including, without limitation, risks associated with: the risk that the results of preclinical studies and clinical trials may not be predictive of future results in connection with current and future clinical trials uncertainties inherent in the initiation, timing and design of future clinical trials, the availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results of early clinical trials will be indicative of the results of later clinical trials, the ability to successfully demonstrate the safety and efficacy of drug candidates, the timing and outcome of planned interactions with regulatory authorities and other factors. These risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the most recent Quarterly Report on Form 10-Q and in subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our view as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor and Media Contact:
Justine Koenigsberg
Vice President, Investor Relations
investors@kymeratx.com
media@kymeratx.com
857-285-5300
FAQ
What tumor types showed sensitivity to Kymera's KT-253 degrader (KYMR)?
What is the current development stage of Kymera's KT-253 (KYMR)?
What will Kymera Therapeutics (KYMR) present at the EORTC-NCI-AACR 2024 Symposium?
